In the Journals

CNV recurs up to 6 years after PDT, anti-VEGF injections

Myopic choroidal neovascularization recurred in almost half of patients who underwent photodynamic therapy with or without intravitreal injections of anti-VEGF agents, according to a study.

“Presence of lacquer crack, absence of dark rim and prior photodynamic therapy are risk factors for long-term recurrence of myopic choroidal neovascularization after treatment,” the study authors said.

The retrospective study included 76 eyes of 76 myopic patients with choroidal neovascularization (CNV) who underwent photodynamic therapy (PDT) alone or combined with intravitreal anti-VEGF injections.

Fifty-four eyes (71.1%) underwent PDT as initial treatment and 15 eyes (19.7%) underwent intravitreal anti-VEGF injection as initial treatment. Seven eyes (9.2%) underwent combined treatment.

Investigators assessed best corrected visual acuity and axial length and used fundus photography, optical coherence tomography (OCT) and fluorescein angiography to identify anatomic signs of CNV.

Mean patient age was 42.74 years. Mean follow-up was 71.21 months.

Overall, at least one recurrence was identified in 35 eyes (46.1%). The mean interval between initial treatment and the first recurrence was 24.15 months.

Twenty-eight eyes in the PDT group (51.9%), four eyes in the combination treatment group (20%) and three eyes in the anti-VEGF group (20%) had at least one recurrence.

Presence of lacquer crack, prior PDT and absence of dark rim correlated significantly with recurrence of myopic CNV (P = .012, P = .027 and P = .020, respectively), the authors said.

Disclosure: The study authors report no relevant financial disclosures.

Myopic choroidal neovascularization recurred in almost half of patients who underwent photodynamic therapy with or without intravitreal injections of anti-VEGF agents, according to a study.

“Presence of lacquer crack, absence of dark rim and prior photodynamic therapy are risk factors for long-term recurrence of myopic choroidal neovascularization after treatment,” the study authors said.

The retrospective study included 76 eyes of 76 myopic patients with choroidal neovascularization (CNV) who underwent photodynamic therapy (PDT) alone or combined with intravitreal anti-VEGF injections.

Fifty-four eyes (71.1%) underwent PDT as initial treatment and 15 eyes (19.7%) underwent intravitreal anti-VEGF injection as initial treatment. Seven eyes (9.2%) underwent combined treatment.

Investigators assessed best corrected visual acuity and axial length and used fundus photography, optical coherence tomography (OCT) and fluorescein angiography to identify anatomic signs of CNV.

Mean patient age was 42.74 years. Mean follow-up was 71.21 months.

Overall, at least one recurrence was identified in 35 eyes (46.1%). The mean interval between initial treatment and the first recurrence was 24.15 months.

Twenty-eight eyes in the PDT group (51.9%), four eyes in the combination treatment group (20%) and three eyes in the anti-VEGF group (20%) had at least one recurrence.

Presence of lacquer crack, prior PDT and absence of dark rim correlated significantly with recurrence of myopic CNV (P = .012, P = .027 and P = .020, respectively), the authors said.

Disclosure: The study authors report no relevant financial disclosures.